- Home
- WERN vs AUPH Comparison
WERN vs AUPH Comparison
Compare WERN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WERN | AUPH |
|---|---|---|
| Founded | 1956 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WERN | AUPH |
|---|---|---|
| Price | $37.06 | $16.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $33.79 | $17.25 |
| AVG Volume (30 Days) | 726.2K | ★ 921.0K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | 0.03 | ★ 0.53 |
| Revenue | ★ $2,974,396,000.00 | $283,055,000.00 |
| Revenue This Year | $22.24 | $17.54 |
| Revenue Next Year | $6.33 | $15.74 |
| P/E Ratio | $1,296.33 | ★ $30.66 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $23.06 | $10.34 |
| 52 Week High | $47.49 | $19.25 |
Technical Indicators
Market Signals| Indicator | WERN | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 50.24 |
| Support Level | $36.06 | $15.55 |
| Resistance Level | $38.82 | $16.40 |
| Average True Range (ATR) | 1.37 | 0.38 |
| MACD | 0.19 | -0.04 |
| Stochastic Oscillator | 39.48 | 13.95 |
Price Performance
Historical ComparisonAbout WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.